MET and hepatocellular carcinoma: However, the negative results of the “Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma” (METIV-HCC) phase III randomized trial, showing that tivantinib did not improve overall survival compared with placebo in patients with c-MET-high advanced hepatocellular carcinoma, suggest that additional studies are needed to find biomarkers to identify the subsets of patients more sensitive to c-MET inhibition [47].